1 证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202101 | --- | --- | --- | |-----------------------|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 □ □ 媒体采访 □ | 分析师会议 业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 □ □ 现场参观 ■ 其他 （电话会议） | 路演活动 | | | 中泰证券谢木青 & 李 | 建、广发证券漆经纬、建信理财、天弘基金、 | | | | 国泰基金、上海慈阳资管、上海河清资管、丹羿投资、顶天投资、 | | 参与单位名称及 | 阳光资产、中金资管、 | Panview Capital 、建信理财、中银基金、诺 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202104 | --- | --- | --- | |----------------|----------------------------------|---------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | ■ □ 媒体采访 □ | □ 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | | | | □ 其他 | | | | 钟港资本 尤娜 | | | | 国泰基金 秦培栋、程瑶 | | | 参与单位名称及 | 国盛证券 李顺帆 | | | 人员姓名 | 华泰资管 蔡轩 | | | | 中银基金 钱嘉鎏 | | | | 个人投资者 | 王晓静（授权徐书剑代表参会） | | 时间 | 2021 年 11 月 3 日 | 10 ： 30-11 ： 40 | | | 2021 年 11 月 4 日 | 14 ： 00-15 ： ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202201 | --- | --- | --- | --- | --- | --- | |-----------------------------|-----------------------------------------------------|------------|------------------------------------|--------------------------------|-------| | | | | | | | | | □ 特定对象调研 | 分析师会议 | □ | | | | | □ 媒体采访 | 业绩说明会 | ■ | | | | 投资者关系活动 | □ 新闻发布会 | 路演活动 | □ | | | | 类别 | □ 现场参观 | | | | | | | □ 其他 | | | | | | 参与单位名称及 | 参与公司 2021 | | 年度网上业绩说明会的投资者 | | | | 人员姓名 时间 | 2022 年 5 月 6 日 15 | ： 00 | 00-17 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202206 | --- | --- | --- | --- | --- | |-----------------------|-------------------------------------------------------|---------------------------|---------------------------------------------------------|----------------------------| | | | | | | | | □ 特定对象调研 | 分析师会议 | □ | | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | | | 类别 | □ 新闻发布会 | 路演活动 | □ | | | | □ 现场参观 | | | | | | ■ 其他（山东辖区上市公司 | 2022 | | 年度投资者网上集体接待日） | | 参与单位名称及 | | | 通过全景网"投资者关系互动平台"远程参与"山东辖区上市公司 | | | 人员姓名 | 2 ...

证券代码：002382 证券简称：蓝帆医疗 公告编号：2022-082 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 关于参加山东辖区上市公司2022年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与广大投资者的互动交流，蓝帆医疗股份有限公司（以下简称"公 司"）将参加由中国证券监督管理委员会山东监管局及山东上市公司协会联合举办， 深圳市全景网络有限公司（以下简称"全景网"）承办的 "山东辖区上市公司 2022 年 度投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将全景网提供的网上平台采取网络远程的方式举 行，投资者可以登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次投资者 集体接待日活动，活动时间为 2022 年 11 月 16 日（星期三）下午 14:00-16:00。 届时公司董事长刘文静女士，董事、总裁钟舒乔先生，副总裁、首席财务官崔运 涛先生，副总裁、董事会秘书兼首席法务官黄婕女士将通过网络在线形式与投资者进 行沟通交 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202203 | --- | --- | --- | --- | |------------------------------|------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------| | | □ 特定对象调研 □ | 分析师会议 | | | | □ 媒体采访 □ | 业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □ | 路演活动 | | | 类别 | □ 现场参观 ■ 其他 （研发开放日） | | | | | | | 西南证券、前海鸿富基金、高毅资产、兴业基金、信达证券、东方 | | 参与单位名称及 人员姓名 时间 | 国海证券等 17 家机构 2022 年 9 月 9 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202202 | --- | --- | --- | |---------------------------------------------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 □ | 业绩说明会 | | 投资者关系活动 类 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202204 | --- | --- | --- | |-----------------------------|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 □ | 分析师会议 | | | □ 媒体采访 □ | 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 □ | 路演活动 | | 类别 | □ 现场参观 ■ 其他 （电话会议） | | | 参与单位名称及 | 中金基金等 7 家机构投资者 | 信达证券、民生加银、信达澳亚、大成基金、安信基金、万家基金、 | | 人员姓名 | | | | 时间 | 2022 年 10 月 12 日 10 | ： 00-11 ： 00 | | 地点 | ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202205 | --- | --- | --- | --- | --- | |---------------------|---------------------------------------------------------|----------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | □ 特定对象调研 □ | 分析师会议 | | | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | | | 类别 参与单位名称及 | □ 新闻发布会 □ □ 现场参观 ■ 其他 （电话会议） | 路演活动 | | 信达证券、中金公司、 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,181,534,505.69, a decrease of 14.68% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥35,721,598.27, an increase of 255.91% year-on-year[6]. - Total operating revenue decreased by 281.72 million yuan, a decline of 42.86% year-on-year, primarily due to a significant drop in product prices despite increased sales volume in the protective division[24]. - Total operating revenue for the current period is approximately $3.76 billion, a decrease of 43% compared to $6.57 billion in the previous period[48]. - Net profit for the current period is approximately -$144.71 million, a significant decline from a net profit of approximately $3.42 billion in the previous period[52]. - The company's total liabilities decreased to approximately $5.19 billion from $6.38 billion in the previous period, reflecting a reduction of about 18.5%[47]. - Total equity attributable to shareholders increased to approximately $10.89 billion from $10.54 billion, marking an increase of about 3.3%[47]. - The company reported a basic earnings per share of -$0.14, down from $3.41 in the previous period[54]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥255,284,295.68, down 89.80% compared to the same period last year[6]. - Net cash flow from operating activities decreased by ¥2,248,119,610.38, down 89.80% year-on-year, primarily due to a reduction in cash received from sales of goods and services[29]. - The net cash flow from investment activities increased by ¥1,933,153,351.07, a growth of 100.22% year-on-year, mainly due to a decrease in cash outflows from investment activities[29]. - The net cash flow from financing activities increased by ¥865,292,517.73, a growth of 91.74% year-on-year, primarily due to a decrease in cash outflows from financing activities[29]. - The net cash flow from financing activities is -¥77,878,992.48, an improvement from -¥943,171,510.21 in the previous period[58]. - The total cash inflow from operating activities is ¥4,572,872,519.96, compared to ¥7,094,474,464.85 in the previous period, indicating a decline[55]. - Cash outflow from operating activities is ¥4,317,588,224.28, slightly reduced from ¥4,591,070,558.79 in the previous period[55]. - The company reported a cash increase of ¥271,074,854.39 for the current period, contrasting with a decrease of -¥430,277,528.98 in the previous period[58]. Assets and Liabilities - The total assets at the end of Q3 2022 were ¥16,076,004,157.87, a decrease of 4.95% from the end of the previous year[6]. - As of September 30, 2022, the total assets of the company amounted to ¥16,076,004,157.87, a decrease from ¥16,913,875,507.52 at the beginning of the year[41]. - The company's current assets totaled ¥4,679,774,966.03, down from ¥6,341,271,206.34 at the start of the year, indicating a decline of approximately 26.2%[44]. - The cash and cash equivalents were reported at ¥2,337,904,523.45, a decrease of 17.6% from ¥2,839,863,972.31 at the beginning of the year[41]. - Inventory decreased to ¥941,431,001.04 from ¥1,124,536,355.21, reflecting a reduction of about 16.2%[44]. - The company's non-current assets increased to ¥11,396,229,191.84 from ¥10,572,604,301.18, representing an increase of approximately 7.8%[44]. - Short-term borrowings rose significantly to ¥142,301,550.94 from ¥12,559,546.52, indicating a substantial increase in leverage[44]. - Total current liabilities decreased to ¥2,204,557,956.88 from ¥3,184,141,878.69, a reduction of about 30.8%[44]. Investment and Income - Investment income increased by ¥215,095,508.60, a growth of 561.24% compared to the same period last year, primarily due to reclassification of accounting for Tongxin Medical[27]. - The company reported a significant increase in investment income to approximately $253.42 million from $38.33 million in the previous period[52]. - Other income increased by ¥7,083,297.66, a growth of 129.28% year-on-year, mainly due to an increase in government subsidies unrelated to daily operations[27]. Division Performance - The cardiovascular division reported a profit of ¥6,353,500 for the first three quarters, driven by a significant investment in high-end medical devices and a shift in accounting treatment for a joint venture[11]. - The sales volume of glove products in the protective division exceeded 24 billion pieces, representing a growth of over 30% year-on-year[14]. - The market share of the company's nitrile gloves in the domestic export market increased from 10.86% in the first three quarters of 2021 to 20.26% in 2022, ranking second nationally[14]. - The nursing division achieved a cumulative profit of 25.75 million yuan in the first three quarters, representing a year-on-year growth of over 50%[15]. - Domestic market revenue for the nursing division grew by over 40% compared to the same period last year[15]. - The emergency kit product line continues to be a key focus, with significant growth potential expected due to capacity expansion projects[15]. Regulatory and Strategic Developments - The company announced the approval of its subsidiary's "U-Mo Coated Coronary Balloon Dilation Catheter" by the NMPA in China, enhancing its product portfolio[40]. - The company has applied for bank credit for its wholly-owned subsidiary, indicating a strategy for financial support and expansion[40]. - The company established partnerships with well-known enterprises such as Didi Chuxing and China Life to provide customized emergency solutions[15]. - The company confirmed share-based payment expenses of ¥34 million related to its core management and technical staff incentive plan[11]. Other Financial Metrics - The weighted average return on equity was 0.33% for Q3 2022, compared to -1.35% for the same period last year[6]. - Other comprehensive income increased by 460.97 million yuan, a growth of 406.29% year-on-year, primarily due to exchange rate fluctuations[19]. - Fair value changes decreased by ¥1,097,283,154.50, a decline of 100.13% year-on-year, mainly due to last year's significant asset restructuring performance compensation[27]. - Asset impairment losses increased by ¥46,552,509.93, a growth of 87.14% year-on-year, primarily due to increased inventory write-down provisions[27].